Avanos Medical (AVNS) was recently removed from both the Russell 2000 Defensive Index and the Russell 2000 Value-Defensive Index. This change can influence index-tracking fund flows and institutional trading patterns.

At a share price of $24.92, Avanos Medical has seen a 90-day share price return of 79.02% and a year-to-date share price return of 122.90%. The 1-year total shareholder return of 102.11% contrasts with weaker 3- and 5-year total shareholder returns, suggesting that recent momentum has picked up after a tougher stretch for long-term holders.

If this kind of sharp shift in sentiment has your attention, it could be a good moment to widen your search using the 40 healthcare AI stocks

After a surge like Avanos Medical has just posted, the debate quickly shifts to whether the bulk of the upside is already in the rearview mirror or if the repricing has only just started. How do current fundamentals stack up against this new share price?

Preferred Price-to-Sales of 1.6x: Is it justified?

For Avanos Medical, the preferred valuation anchor right now is its P/S ratio of 1.6x, which sits above the stock's estimated fair P/S of 1.2x but below key peer benchmarks.

The P/S ratio compares the total market value of the company to its annual revenue, so it reflects how much investors are currently paying for each dollar of Avanos Medical's $715.9 million in sales.

On one side, Avanos Medical is described as expensive relative to its estimated fair P/S ratio of 1.2x, a level the market could potentially move toward if sentiment or fundamentals shift. On the other side, its 1.6x multiple screens as good value against both the broader US Medical Equipment industry average of 2.9x and a peer average of 2.2x. This highlights how the stock is priced at a discount to many comparables despite being unprofitable, with losses over the past 5 years and a negative return on equity.

Against industry and peer benchmarks, that 1.6x P/S stands out as meaningfully lower, even as the fair ratio work suggests there is less room based purely on historical relationships between sales and valuation.

Result: Price-to-Sales of 1.6x (ABOUT RIGHT)

However, the story around Avanos Medical can change quickly if its recent loss of $74.4 million persists or if its revenue growth of 2.0% slows or reverses.

Next Steps

If the recent enthusiasm around Avanos Medical feels compelling but incomplete, this is a good time to review the details and quickly decide where you stand, including its 2 important warning signs

Looking for more investment ideas beyond Avanos Medical?

If Avanos Medical has sharpened your focus, do not stop here. Widening your watchlist now can help you spot opportunities before they get crowded.

• Target potential value opportunities by scanning companies that appear mispriced on quality and fundamentals with the 45 high quality undervalued stocks
• Prioritize stability by reviewing companies that pass strict balance sheet and fundamentals checks through the solid balance sheet and fundamentals stocks screener (47 results)
• Hunt for under-the-radar opportunities before they gain attention using the screener containing 18 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.